Insider Selling: Aquestive Therapeutics (NASDAQ:AQST) Director Sells $125,500.00 in Stock

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Director Julie Krop sold 25,000 shares of the stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $5.02, for a total value of $125,500.00. Following the sale, the director directly owned 25,000 shares of the company’s stock, valued at $125,500. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Aquestive Therapeutics Stock Up 2.7%

Aquestive Therapeutics stock traded up $0.14 during mid-day trading on Wednesday, reaching $5.17. 1,004,140 shares of the company’s stock were exchanged, compared to its average volume of 3,172,293. The business’s fifty day simple moving average is $4.20 and its 200 day simple moving average is $4.41. Aquestive Therapeutics, Inc. has a one year low of $2.93 and a one year high of $7.55. The firm has a market capitalization of $647.95 million, a PE ratio of -8.40 and a beta of 1.46.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.07. The business had revenue of $14.45 million during the quarter, compared to the consensus estimate of $10.90 million. On average, sell-side analysts forecast that Aquestive Therapeutics, Inc. will post -0.41 earnings per share for the current year.

Institutional Investors Weigh In On Aquestive Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Arete Wealth Advisors LLC purchased a new stake in shares of Aquestive Therapeutics in the first quarter worth about $504,000. Bank of America Corp DE grew its stake in Aquestive Therapeutics by 99.2% during the first quarter. Bank of America Corp DE now owns 2,405,050 shares of the company’s stock valued at $9,981,000 after acquiring an additional 1,197,459 shares in the last quarter. ADAR1 Capital Management LLC increased its holdings in Aquestive Therapeutics by 103.9% during the 1st quarter. ADAR1 Capital Management LLC now owns 10,000 shares of the company’s stock worth $42,000 after acquiring an additional 264,000 shares during the period. Royal Bank of Canada lifted its stake in Aquestive Therapeutics by 133.0% in the 1st quarter. Royal Bank of Canada now owns 28,951 shares of the company’s stock worth $120,000 after purchasing an additional 16,525 shares in the last quarter. Finally, Quantinno Capital Management LP lifted its stake in Aquestive Therapeutics by 52.8% in the 1st quarter. Quantinno Capital Management LP now owns 18,014 shares of the company’s stock worth $75,000 after purchasing an additional 6,221 shares in the last quarter. 32.45% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Wall Street Zen raised shares of Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Aquestive Therapeutics in a research note on Monday, April 20th. Finally, Oppenheimer assumed coverage on shares of Aquestive Therapeutics in a report on Friday, April 24th. They issued an “outperform” rating and a $8.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $8.50.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.